Answers are grounded in this paper and cite their sources.
Shows that physiological roles of reactive oxygen species oppose oxidative stress in cardioprotection, suggesting simple antioxidant removal impairs clinical trial success.
homeostasis, thiol group redox balance, hydrogen sulfide modulation, cross-talk with NAPDH oxidases, exosomes, cytokines and growth factors. While mechanistic insights are needed to improve our current therapeutic approaches, advancements in knowledge of ROS-mediated processes indicate that detrimental facets of oxidative stress are opposed by ROS requirement for physiological and protective reactions. This inevitable contrast is likely to underlie unsuccessful clinical trials and limits the development of novel cardioprotective interventions simply based upon ROS removal.
No takes yet. Share an insight, caveat, or question.
Heusch et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: